Antibacterial effect of plasma rich in growth factors (PRGF (R)-Endoret (R)) against Staphylococcus aureus and Staphylococcus epidermidis strains

Biotechnology Institute (BTI ImasD), Vitoria, Spain.
Clinical and Experimental Dermatology (Impact Factor: 1.09). 02/2012; 37(6):652-7. DOI: 10.1111/j.1365-2230.2011.04303.x
Source: PubMed


Formulations containing plasma rich in growth factors (PRGF) are opening new avenues in the field of regenerative medicine.
To evaluate the potential antimicrobial effects of a product (plasma rich in growth factors; PRGF(®)-Endoret(®)) against both methicillin-sensitive and methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. The potential effect of incorporating the patient's leucocytes into the PRGF formulation (F3+leu) was also studied.
Blood samples were obtained from five healthy volunteers and used to prepare each type of PRGF (F1, F3 and F3+leu). Various biological assays were performed to compare the characteristics of the different formulations, including measurement of the concentration of platelets and leucocytes, and assays of coagulation. The microbiological activity of PRGF-Endoret against both staphylococcal strains was performed by counting the number of the surviving bacterial colonies after incubation at 0, 4 and 8 h with the different formulations.
The three PRGF-Endoret formulations evaluated were enriched in platelets by 1.10, 2.57 and 1.89 times, respectively, and the leucocyte concentration in the F3+leu sample was increased by 3.9 times. We found that all formulations had a strong bacteriostatic effect, especially in the first 4 h after application. All formulations had an antibacterial effect at 4 h for three of the four strains, with the exception of methicillin-sensitive S. epidermidis. No differences in the bacterial inhibitory effect were found between the formulations.
This is the first time different formulations of this product have been evaluated, and the results suggest that PRGF-Endoret could be used in the fight against postoperative and wound infections.


Available from: Francisco Muruzabal, Sep 17, 2014
    • "In vitro studies investigating the antibacterial effects of either equine or human PC and/or PG have focused on whether these substances can inhibit bacterial growth over time [25] [26] [32] and whether this antimicrobial effect is dependent on leukocyte activity [27] [36]. However, these studies have not evaluated whether these bacteria induce the degradation of key GFs present in PRP, such as TGF-b 1 and PDGF-BB. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aims of this study were (1) to evaluate the antibacterial effects of equine platelet concentrates (PCs) and other blood-derived preparations on methicillin-resistant Staphylococcus aureus (MRSA); (2) to determine the effect of MRSA on the concentration of transforming growth factor beta 1 and platelet-derived growth factor BB over time; and (3) to determine the correlations between MRSA growth and blood cell counts (platelets and leukocytes), as well as growth factor (GF) concentrations, in PCs and other blood-derived preparations. Blood from 14 clinically healthy horses was used to prepare the different blood-derived preparations. Bacterial growth was significantly inhibited by the different PCs and the cell-free plasma products, mainly during the first 8 hours. Growth factor concentrations were not significantly affected by the presence of bacteria. No correlation between MRSA growth inhibition and blood cells and/or GFs was found. The in vitro bacteriostatic effect of PCs on MRSA could be predominantly attributed to the plasma complement.
    Journal of Equine Veterinary Science 03/2015; 35(3). DOI:10.1016/j.jevs.2015.01.001 · 0.87 Impact Factor
    • "Plasma rich in growth factors (PRGF) is an autologous platelet rich plasma, that may represent a turning point in the use of bloodderivates in ophthalmology. By concentrating the platelets and avoiding the leukocytes, PRGF increases the amount of EGF, PDGF and FGF (Nurden et al., 2008) exerting multiple biological and antimicrobial properties (Anitua et al., 2012, 2008, 2009). Recent evidences suggest that PRGF is a potential approach for the treatment of several ocular surface diseases including dry eye, persistent corneal defects and ulcers, obtaining successful results even in those patients where autologous serum was ineffective (Lopez- Plandolit et al., 2010, 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Autologous serum (AS) eye drops was the first blood-derived product used for the treatment of corneal pathologies but nowadays PRGF arises as a novel interesting alternative to this type of diseases. The purpose of this study was to evaluate and compare the biological outcomes of autologous serum eye drops or Plasma rich in growth factors (PRGF) eye drops on corneal stromal keratocytes (HK) and conjunctival fibroblasts (HConF). To address this, blood from healthy donors was collected and processed to obtain autologous serum (AS) eye drops and plasma rich in growth factors (PRGF) eye drops. Blood-derivates were aliquoted and stored at -80°C until use. PDGF-AB, VEGF, EGF, FGFb and TGF-β1 were quantified. The potential of PRGF and AS in promoting wound healing was evaluated by means of proliferation and migration assays in HK and HConF. Fibroblast cells were induced to myofibroblast differentiation after treatment with 2.5ng/mL of TGF-β1. The capability of PRGF and AS to prevent and inhibit TGF-β1-induced differentiation was evaluated. Results showed significant higher levels of all growth factors analyzed in PRGF eye drops compared to AS. Moreover, PRGF eye drops enhanced significantly the biological outcomes of both HK and HConF, and reduced TGF-β1-induced myofibroblast differentiation in contrast to autologous serum eye drops (AS). In summary, these results suggest that PRGF exerts enhanced biological outcomes than AS. PRGF may improve the treatment of ocular surface wound healing minimizing the scar formation compared to AS. Results obtained herein suggest that PRGF protects and reverses the myofibroblast phenotype while promotes cell proliferation and migration. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Experimental Eye Research 02/2015; 135. DOI:10.1016/j.exer.2015.02.016 · 2.71 Impact Factor
  • Source
    • "To evaluate the quality of the P-PRP produced, platelet and leukocyte counts were performed using a hematology analyzer (XE-2100, Sysmex Europe, Norderstedt, Germany). According to Anitua et al., platelet concentration in P-PRP is at least twice the concentration in whole blood, while leukocyte concentration is consistently lower (<103 white blood cells/µl) [8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Autologous platelet concentrates are successfully adopted in a variety of medical fields to stimulate bone and soft tissue regeneration. The rationale for their use consists in the delivery of a wide range of platelet-derived bioactive molecules that promotes wound healing. In addition, antimicrobial properties of platelet concentrates have been pointed out. In this study, the effect of the platelet concentration, of the activation step and of the presence of plasmatic components on the antimicrobial activity of pure platelet-rich plasma was investigated against gram positive bacteria isolated from oral cavity. The antibacterial activity, evaluated as the minimum inhibitory concentration, was determined through the microdilution two-fold serial method. Results seem to suggest that the antimicrobial activity of platelet-rich plasma against Enterococcus faecalis, Streptococcus agalactiae, Streptococcus oralis and Staphylococcus aureus is sustained by a co-operation between plasma components and platelet-derived factors and that the activation of coagulation is a fundamental step. The findings of this study may have practical implications in the modality of application of platelet concentrates.
    PLoS ONE 09/2014; 9(9):e107813. DOI:10.1371/journal.pone.0107813 · 3.23 Impact Factor
Show more